Key result
Long-term combination therapy with vasodilators, anticoagulants, and nocturnal oxygen resulted in a 34% fall in mean pulmonary artery pressure and a 51% reduction in total pulmonary vascular resistance.
Why the study?
Does combination therapy with nocturnal oxygen, vasodilators, and anticoagulants improve hemodynamics in a patient with primary pulmonary hypertension?
Case Report (n=1)
Does combination therapy with nocturnal oxygen, vasodilators, and anticoagulants improve hemodynamics in a patient with primary pulmonary hypertension?
Combination therapy with nocturnal oxygen, vasodilators, and anticoagulants may improve hemodynamics in selected patients with primary pulmonary hypertension.
Successful vasodilator therapy of a 19 year old woman with primary pulmonary hypertension is described. Long-term home oxygen therapy during sleep (2 1/min, 8 hours) in combination with vasodilator drugs (prazosin 2 mg and long-acting ISDN 20 mg bid) and an anticoagulant (ticlopidine 100 mg bid) brought significant reduction of pulmonary artery pressure and a rise of cardiac output 3 years later. This combination therapy may be effective in selected patients with primary pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Kanemoto et al. (1989) conducted a case report in Primary pulmonary hypertension (n=1). Vasodilator, anticoagulant, and nocturnal oxygen therapy vs. Baseline was evaluated on Mean pulmonary artery pressure (34% reduction). Long-term combination therapy with vasodilators, anticoagulants, and nocturnal oxygen resulted in a 34% fall in mean pulmonary artery pressure and a 51% reduction in total pulmonary vascular resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: